<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39416744</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1394-195X</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Malaysian journal of medical sciences : MJMS</Title><ISOAbbreviation>Malays J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Epidemiology of Morbidity and Mortality of COVID-19 Patients During the Period of June 2020-September 2021 in Sulianti Saroso Infectious Disease Hospital, Indonesia.</ArticleTitle><Pagination><StartPage>215</StartPage><EndPage>230</EndPage><MedlinePgn>215-230</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21315/mjms2024.31.5.15</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The increasing mortality rate of COVID-19 has remained an international public health concern. Limited studies on clinical treatment and morbidity in hospital settings are available in Indonesia. This present study aims to analyse demographic characteristics, clinical signs and treatment in COVID-19 patients and their association to the mortality case in Sulianti Saroso Infectious Disease Hospital.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The study applied a retrospective cohort approach to all COVID-19 inpatients confirmed by polymerase chain reaction (PCR) testing in Sulianti Saroso Infectious Disease Hospital from 1 June 2020 to 30 September 2021. Overall survival rates until the end of the study were calculated using the Kaplan-Meier method and compared using the log-rank test. A Cox regression model was used to evaluate the crude and adjusted hazard ratios for associated factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We collected 1,970 inpatient data that met our inclusion and exclusion criteria. Most of them were 19 years old-59 years old (73.2%) and male (52.6%), and 966 (49%) patients had comorbidities. Approximately 63.9%, 89.2%, 89.8%, 82%, and 14.1% of the patients had ferritin levels ≤ 800, received antiviral treatment, were treated in non-intensive wards, had a moderate or mild clinical stage and did not survive, respectively. In the adjusted analysis, mortality was associated with sex (hazard ratio [HR]: 1.12; 95% CI: 1.02, 1.23), presence of comorbidity (HR: 1.19; 95% CI: 1.08, 1.30) and favipiravir (FPV) plus azithromycin treatment (HR: 1.21; 95% CI: 1.06,1.39). FPV treatment (HR: 1.35; 95% CI: 1.04, 1.75) was associated with higher mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Tailored approaches to treatment, considering individual risk factors and comorbidities, are crucial in improving patient outcomes.</AbstractText><CopyrightInformation>© Penerbit Universiti Sains Malaysia, 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sitompul</LastName><ForeName>Pompini Agustina</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Pulmonology Department, Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariana</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Research Department, Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maemun</LastName><ForeName>Siti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Department, Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, University of Respati Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widiantari</LastName><ForeName>Aninda Dinar</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Research Department, Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murtiani</LastName><ForeName>Farida</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Research Department, Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosamarlina</LastName><ForeName>Rosamarlina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pulmonology Department, Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusli</LastName><ForeName>Adria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pulmonology Department, Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundari</LastName><ForeName>Titi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pulmonology Department, Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purnama</LastName><ForeName>Tri Bayu</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Public Health, Universitas Islam Negeri Sumatera Utara, Medan, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Malaysia</Country><MedlineTA>Malays J Med Sci</MedlineTA><NlmUniqueID>101126308</NlmUniqueID><ISSNLinking>1394-195X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">hazard ratio</Keyword><Keyword MajorTopicYN="N">treatments</Keyword></KeywordList><CoiStatement>Conflict of Interest: None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>4</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39416744</ArticleId><ArticleId IdType="pmc">PMC11477462</ArticleId><ArticleId IdType="doi">10.21315/mjms2024.31.5.15</ArticleId><ArticleId IdType="pii">15mjms3105_oa</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khalili M, Karamouzian M, Nasiri N, Javadi S, Mirzazadeh A, Sharifi H. Epidemiological characteristics of COVID-19: a systematic review and meta-analysis. Epidemiol Infect. 2020;148:e130. doi: 10.1017/S0950268820001430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268820001430</ArticleId><ArticleId IdType="pmc">PMC7343974</ArticleId><ArticleId IdType="pubmed">32594937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Choe YJ, Jeong JY. Understanding and interpretation of case fatality rate of coronavirus disease 2019. J Korean Med Sci. 2020;35(12):e137. doi: 10.3346/jkms.2020.35.e137.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e137</ArticleId><ArticleId IdType="pmc">PMC7105506</ArticleId><ArticleId IdType="pubmed">32233163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunadi, Hakim MS, Wibawa H, Marcellus, Setiawaty V, Slamet, et al. Is the infection of the SARS-CoV-2 Delta variant associated with the outcomes of COVID-19 patients? Front Med (Lausanne) 2021;8:780611. doi: 10.3389/fmed.2021.780611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.780611</ArticleId><ArticleId IdType="pmc">PMC8695874</ArticleId><ArticleId IdType="pubmed">34957154</ArticleId></ArticleIdList></Reference><Reference><Citation>Setiadi W, Rozi IE, Safari D, Daningrat WOD, Johar E, Yohan B, et al. Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: a single center study. PLoS ONE. 2022;17(5):e0268241. doi: 10.1371/journal.pone.0268241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268241</ArticleId><ArticleId IdType="pmc">PMC9098020</ArticleId><ArticleId IdType="pubmed">35550635</ArticleId></ArticleIdList></Reference><Reference><Citation>Harapan BN, Harapan T, Theodora L, Anantama NA. From archipelago to pandemic battleground: unveiling Indonesia’s COVID-19 crisis. J Epidemiol Global Health. 2023;13(4):591–603. doi: 10.1007/s44197-023-00148-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44197-023-00148-7</ArticleId><ArticleId IdType="pmc">PMC10686963</ArticleId><ArticleId IdType="pubmed">37707715</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 B. 1.1.529 (Omicron) variant - United States, December 1–8, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(50):1731–1734. doi: 10.15585/mmwr.mm7050e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7050e1</ArticleId><ArticleId IdType="pmc">PMC8675659</ArticleId><ArticleId IdType="pubmed">34914670</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitorus RJ, Yudi Antara N, Elviani R, Ahmad Z, Hudari H, Sangalang RV. The risk factor for mortality in COVID-19 patients in Mohammad Hoesin Hospital, Palembang, Indonesia. Jurnal Ilmu Kesehatan Masyarakat. 2021;12(1):69–76. doi: 10.26553/jikm.2021.12.1.69-76.</Citation><ArticleIdList><ArticleId IdType="doi">10.26553/jikm.2021.12.1.69-76</ArticleId></ArticleIdList></Reference><Reference><Citation>Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study. Lancet Reg Health West Pac. 2021;9:100108. doi: 10.1016/j.lanwpc.2021.100108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100108</ArticleId><ArticleId IdType="pmc">PMC7924904</ArticleId><ArticleId IdType="pubmed">33681830</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2020;92(10):1875–1883. doi: 10.1002/jmv.26050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26050</ArticleId><ArticleId IdType="pmc">PMC7280666</ArticleId><ArticleId IdType="pubmed">32441789</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. doi: 10.1007/s00134-020-05991-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Yang X, Yang L, Zou X, Wang Y, Wu Y, et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care. 2020;24(1):394. doi: 10.1186/s13054-020-03098-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03098-9</ArticleId><ArticleId IdType="pmc">PMC7336107</ArticleId><ArticleId IdType="pubmed">32631393</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto A, Quiñones-Laveriano DM, Azañero J, Chumpitaz R, Claros J, Salazar L, et al. Mortality and associated risk factors in patients hospitalized due to COVID-19 in a Peruvian reference hospital. PLoS ONE. 2022;17(3):e0264789. doi: 10.1371/journal.pone.0264789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0264789</ArticleId><ArticleId IdType="pmc">PMC8890646</ArticleId><ArticleId IdType="pubmed">35235613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SJ, Jung SI. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020;52(2):154–164. doi: 10.3947/ic.2020.52.2.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2020.52.2.154</ArticleId><ArticleId IdType="pmc">PMC7335648</ArticleId><ArticleId IdType="pubmed">32537961</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5) doi: 10.1183/13993003.01227-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01227-2020</ArticleId><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt FT, Tercan M, Patmano G, Bingol Tanrıverdi T, Demir HA, Yurekli UF. Can ferritin levels predict the severity of illness in patients with COVID-19? Cureus. 2021;13(1):e12832. doi: 10.7759/cureus.12832.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.12832</ArticleId><ArticleId IdType="pmc">PMC7899245</ArticleId><ArticleId IdType="pubmed">33633875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Ansar Ahmed Z, Siddiqui I, Haroon Rashid N, Mansoor M, Jafri L. Evaluation of serum ferritin for prediction of severity and mortality in COVID-19: a cross sectional study. Ann Med Surg (Lond) 2021;63:102163. doi: 10.1016/j.amsu.2021.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC7879065</ArticleId><ArticleId IdType="pubmed">33614024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajanna A, Krishnegowda R, Govindaiah R. To correlate serum ferritin levels with clinical outcome in COVID-19 patients. Asian J Med Sci. 2021;12:25–29. doi: 10.3126/ajms.v12i5.34371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3126/ajms.v12i5.34371</ArticleId></ArticleIdList></Reference><Reference><Citation>Qeadan F, Tingey B, Gu LY, Packard AH, Erdei E, Saeed AI. Prognostic values of serum ferritin and d-dimer trajectory in patients with COVID-19. Viruses. 2021;13(3) doi: 10.3390/v13030419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030419</ArticleId><ArticleId IdType="pmc">PMC7998367</ArticleId><ArticleId IdType="pubmed">33807920</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wang X, She F, Zhang W, Liu H, Zhao X. Effects of neutrophil-to-lymphocyte ratio combined with interleukin-6 in predicting 28-day mortality in patients with sepsis. Front Immunol. 2021;12:639735. doi: 10.3389/fimmu.2021.639735.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.639735</ArticleId><ArticleId IdType="pmc">PMC8007868</ArticleId><ArticleId IdType="pubmed">33796105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayah W, Berkane I, Guermache I, Sabri M, Lakhal FZ, Yasmine Rahali S, et al. Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19. Cytokine. 2021;141:155428. doi: 10.1016/j.cyto.2021.155428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155428</ArticleId><ArticleId IdType="pmc">PMC7834734</ArticleId><ArticleId IdType="pubmed">33550165</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhu L, Liu L, Zhao XA, Zhang Z, Xue L, et al. Overweight and obesity are risk factors of severe illness in patients with COVID-19. Obesity (Silver Spring) 2020;28(11):2049–2055. doi: 10.1002/oby.22979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22979</ArticleId><ArticleId IdType="pmc">PMC7436536</ArticleId><ArticleId IdType="pubmed">32735706</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069–1076. doi: 10.1007/s42399-020-00363-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00363-4</ArticleId><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Jr, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;146(2):327e4–329.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7423602</ArticleId><ArticleId IdType="pubmed">32522462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakakos A, Bakakos P, Rovina Unraveling the relationship of asthma and COVID-19. J Pers Med. 2021;11(12) doi: 10.1016/j.jaci.2020.06.001N. doi: 10.3390/jpm11121374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.06.001N</ArticleId><ArticleId IdType="doi">10.3390/jpm11121374</ArticleId><ArticleId IdType="pmc">PMC8708521</ArticleId><ArticleId IdType="pubmed">34945846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramírez-Soto MC, Alarcón-Arroyo M, Chilcon-Vitor Y, Chirinos-Pérez Y, Quispe-Vargas G, Solsol-Jacome K, et al. Association between obesity and COVID-19 mortality in Peru: an ecological study. Trop Med Infect Dis. 2021;6(4) doi: 10.3390/tropicalmed6040182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed6040182</ArticleId><ArticleId IdType="pmc">PMC8544728</ArticleId><ArticleId IdType="pubmed">34698315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med. 2020;173(10):773–781. doi: 10.7326/M20-3742.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3742</ArticleId><ArticleId IdType="pmc">PMC7429998</ArticleId><ArticleId IdType="pubmed">32783686</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O’Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diab Endocrinol. 2021;9(6):350–359. doi: 10.1016/S2213-8587(21)00089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00089-9</ArticleId><ArticleId IdType="pmc">PMC8081400</ArticleId><ArticleId IdType="pubmed">33932335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):e24–e32. doi: 10.1016/S2352-3018(20)30305-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(20)30305-2</ArticleId><ArticleId IdType="pmc">PMC7773630</ArticleId><ArticleId IdType="pubmed">33316211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanda D, Minchella PA, Kampamba D, Itoh M, Hines JZ, Fwoloshi S, et al. COVID-19 severity and COVID-19-associated deaths among hospitalized patients with HIV infection - Zambia, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021;70(22):807–810. doi: 10.15585/mmwr.mm7022a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7022a2</ArticleId><ArticleId IdType="pmc">PMC8174678</ArticleId><ArticleId IdType="pubmed">34081684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021;35(12):3444–3454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8559135</ArticleId><ArticleId IdType="pubmed">34725454</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018;11(1):57–70. doi: 10.1080/17474086.2018.1407645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2018.1407645</ArticleId><ArticleId IdType="pubmed">29160119</ArticleId></ArticleIdList></Reference><Reference><Citation>England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, et al. Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes. Blood Rev. 2021;45:100707. doi: 10.1016/j.blre.2020.100707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2020.100707</ArticleId><ArticleId IdType="pmc">PMC7227559</ArticleId><ArticleId IdType="pubmed">32425294</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial. Front Pharmacol. 2021;12:683296. doi: 10.3389/fphar.2021.683296.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.683296</ArticleId><ArticleId IdType="pmc">PMC8443786</ArticleId><ArticleId IdType="pubmed">34539392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ucan A, Cerci P, Efe S, Akgun H, Ozmen A, Yagmuroglu A, et al. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study. Virology J. 2021;18(1):102. doi: 10.1186/s12985-021-01577-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01577-1</ArticleId><ArticleId IdType="pmc">PMC8148395</ArticleId><ArticleId IdType="pubmed">34034765</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, et al. Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: a randomized clinical trial. JAMA. 2021;326(6):490–498. doi: 10.1001/jama.2021.11517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.11517</ArticleId><ArticleId IdType="pmc">PMC8285753</ArticleId><ArticleId IdType="pubmed">34269813</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. New England J Med. 2020;384(8):693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>